01:58 , Jun 29, 2019 |  BioCentury  |  Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
21:58 , May 24, 2019 |  BioCentury  |  Product Development

Why quizartinib hiccup at ODAC shouldn’t derail Daiichi’s 2025 cancer drug goals

FDA's ODAC may have given the thumbs down to Daiichi’s quizartinib, but a stocked pipeline and another ongoing trial of the candidate suggest it’s more of a hiccup than a hurdle in the Japanese pharma’s...
23:40 , Apr 8, 2019 |  BC Extra  |  Company News

Management tracks: WuXi AppTec, Kymab, Acceleron

WuXi AppTec Co. Ltd. (Shanghai:603259; HKSE:2359) hired Frederick Hausheer as CMO. He was CEO of Alpha Omega Oncology Services (San Antonio, Texas) and an associate partner at Alacrita Consulting (Waltham, Mass.). Antibody company Kymab Group...
00:55 , Sep 18, 2015 |  BC Extra  |  Company News

Management tracks

Neurology play Marathon Pharmaceuticals LLC (Northbrook, Ill.) named Jordon Dubow CMO and VP of clinical and medical affairs. Dubow was VP of medical affairs at Cynapsus Therapeutics Inc. (Toronto, Ontario). Regenerative medicine company Osiris Therapeutics...
08:00 , Jan 12, 2015 |  BC Week In Review  |  Company News

Halozyme management update

Halozyme Therapeutics Inc. (NASDAQ:HALO), San Diego, Calif.   Business: Endocrine/Metabolic, Cancer, Dermatology   Hired: Athena Countouriotis as CMO, formerly CMO of Ambit Biosciences Corp. , which Daiichi Sankyo Co. Ltd. acquired  ...
08:00 , Nov 24, 2014 |  BC Week In Review  |  Company News

Ambit, Daiichi Sankyo deal

Daiichi completed its acquisition of Ambit (see BioCentury, Oct. 27). Ambit Biosciences Corp. , San Diego, Calif.   Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan   Business: Cancer  ...
07:00 , Oct 27, 2014 |  BC Week In Review  |  Company News

Ambit, Daiichi Sankyo deal

Daiichi Sankyo began its tender offer to acquire Ambit Biosciences for up to $19.50 per share, or about $415 million on a fully diluted basis. The tender expires at 5 p.m. EST on Nov. 10...
07:00 , Oct 6, 2014 |  BC Week In Review  |  Company News

Ambit, Daiichi Sankyo deal

Daiichi Sankyo will acquire Ambit Biosciences for up to $19.50 per share, or about $415 million on a fully diluted basis. Ambit shareholders will receive $15 per share in cash, or about $315 million, and...
07:00 , Oct 6, 2014 |  BioCentury  |  Finance

3Q14 Stock Wrap-Up: Going big again

For the second quarter in a row, only the large caps finished in the black in 3Q14. In the over $5 billion segment, which was up 9%, gainers outnumbered decliners 22-9, while the decliners led...
02:30 , Sep 30, 2014 |  BC Extra  |  Top Story

CVR boosts Ambit in Daiichi Sankyo deal

Daiichi Sankyo Co. Ltd. (Tokyo:4568) will acquire Ambit Biosciences Corp. (NASDAQ:AMBI) for up to $410 million. The deal includes $315 million in upfront cash, or $15 per share, plus $95 million in commercial milestones in...